Cited 0 times in
유전자 1형 만성 C형간염 환자에서 페그인터페론과 리바비린의 24주와 48주 치료 효과 비교
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김미나 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 전재윤 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2015-04-24T17:42:28Z | - |
dc.date.available | 2015-04-24T17:42:28Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/105915 | - |
dc.description.abstract | Background/Aims: The standard therapy for patients with genotype 1 chronic hepatitis C (CHC) is a combination of peginterferon and ribavirin for 48 weeks. However, the most appropriate duration of treatment remains to be established because of treatment-related side effects and cost. The aim of this study was to compare the efficacies of 24- and 48-week treatments, and to assess the efficacy of split 24-week therapy (a further 24 weeks of treatment in patients with relapse after the initial 24 weeks of treatment). Methods: A total of 130 patients with genotype 1 CHC was treated between June 2004 and December 2006. Patients with undetectable HCV RNA at 24 weeks of treatment (as assessed by qualitative PCR assay; n=101 patients) were allowed to choose either 24 or 48 weeks as the duration of their treatment; 51 patients chose the 24-week treatment regimen and the remainder chose the 48-week regimen. Patients who relapsed after 24 weeks of treatment were treated for further 24 weeks. The sustained virologic response (SVR) of each treatment group was analyzed. Results: The SVR rate was higher in patients treated for 48 weeks than in those treated for 24 weeks (74.0% vs. 52.9%, P=0.028). In the multivariate analysis, age < 50 years, platelets ≥ 150,000/mm3, and treatment duration for 48 weeks remained significant independent predictors of SVR. Fourteen of the 24 patients who relapsed in the 24-week treatment group received split 24-week therapy, and 6 patients (42.9%) achieved SVR. The overall SVR rate did not differ significantly between the 24-week treatment group, including those who underwent 24-week split therapy (64.7%), and the 48-week treatment group (64.7% vs. 74%, P=0.311). Conclusions: The 24-week plus additional split 24-week therapy following failure is a useful treatment strategy for patients with genotype 1 CHC | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 496~503 | - |
dc.relation.isPartOf | Korean Journal of Hepatology (대한간학회지) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Age Factors | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antiviral Agents/administration & dosage* | - |
dc.subject.MESH | Antiviral Agents/therapeutic use | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Hepacivirus/genetics | - |
dc.subject.MESH | Hepatitis C, Chronic/drug therapy* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Interferon-alpha/administration & dosage* | - |
dc.subject.MESH | Interferon-alpha/therapeutic use | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multivariate Analysis | - |
dc.subject.MESH | Polyethylene Glycols/administration & dosage* | - |
dc.subject.MESH | Polyethylene Glycols/therapeutic use | - |
dc.subject.MESH | RNA, Viral/blood | - |
dc.subject.MESH | Recombinant Proteins | - |
dc.subject.MESH | Ribavirin/administration & dosage* | - |
dc.subject.MESH | Ribavirin/therapeutic use | - |
dc.title | 유전자 1형 만성 C형간염 환자에서 페그인터페론과 리바비린의 24주와 48주 치료 효과 비교 | - |
dc.title.alternative | A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | 김미나 | - |
dc.contributor.googleauthor | 윤기태 | - |
dc.contributor.googleauthor | 박준용 | - |
dc.contributor.googleauthor | 김도영 | - |
dc.contributor.googleauthor | 안상훈 | - |
dc.contributor.googleauthor | 전재윤 | - |
dc.contributor.googleauthor | 한광협 | - |
dc.identifier.doi | 10.3350/kjhep.2009.15.4.496 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00440 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A03544 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J02036 | - |
dc.identifier.pmid | 20037268 | - |
dc.subject.keyword | Chronic hepatitis C | - |
dc.subject.keyword | Genotype 1 | - |
dc.subject.keyword | Peginterferon | - |
dc.subject.keyword | Ribavirin | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Mi Na | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Chon, Chae Yoon | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Mi Na | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Chon, Chae Yoon | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.citation.volume | 15 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 496 | - |
dc.citation.endPage | 503 | - |
dc.identifier.bibliographicCitation | Korean Journal of Hepatology (대한간학회지), Vol.15(4) : 496-503, 2009 | - |
dc.identifier.rimsid | 51436 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.